Trial Boosts Cosentyx for Juvenile Arthritis

(MedPage Today) -- A 2-year randomized trial demonstrated that secukinumab (Cosentyx) was effective in reducing disease flares in young patients with different forms of juvenile idiopathic arthritis (JIA), researchers said.
Flares occurred in...